Erasca (ERAS) Jefferies Global Healthcare Conference 2026 summary

Pipeline overview and lead programs

• Two lead RAS-targeting agents, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS reversible binder), are both in phase I trials targeting multiple RAS mutations.

• ERAS-0015 is being evaluated in the AURORAS-1 trial, while ERAS-4001 is in the BOREALIS-1 trial.

• Future plans include a combination trial (Northern Lights) of both agents.

Clinical data and efficacy

• ERAS-0015 showed 60-63% response rates in non-small cell lung cancer at pharmacologically active doses in both U.S. and China, with a global response rate of 62% in RAS-driven G12X NSCLC.

• In docetaxel-eligible NSCLC patients, response rates reached 75%.

• Pancreatic cancer response rates were 41% in China and 27% in the U.S. at recommended doses, with U.S. data still maturing.

• Higher doses (24-32 mg) in the U.S. showed more promising responses in pancreatic cancer compared to lower doses.

• Early colorectal cancer data showed a partial response in combination with panitumumab, suggesting potential synergy.

Safety and tolerability

• Lower frequency and severity of rash, nausea, vomiting, diarrhea, and stomatitis observed with ERAS-0015; dose proportional PK at all doses.

• Fewer dose modifications and grade 3+ rash events (2%) compared to competitors, supporting better tolerability.

• One grade 5 pneumonitis case occurred in a heavily pretreated patient; overall pneumonitis rate was 2.5%, consistent with other targeted therapies.

• No material difference in adverse event rates between 8 mg and higher doses.